ProCE Banner Series

Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3–Targeted ADCs

Improve your knowledge on the safety and efficacy of approved and investigational HER2-, HER3-, TROP2-, and B7-H3–Targeted ADCs for the treatment of lung cancer with an EBAC/ACCME-accredited satellite symposium with live simulcast. Register now! 

  AMA
  | EBAC®
  | EBAC®
Who Should Attend

This program is intended for medical oncologists and other healthcare professionals caring for patients with lung cancer.

All Events

Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3-Targeted ADCs

Past Events

September

16

2024

6:30 PM - 8:00 PM Central European Summer Time (CEST)

In-personVirtual

Fira Barcelona Gran Via, Av. Joan Carles I, 64 08908, L'Hospitalet de Llobregat, Barcelona, Spain

Faculty

ProCE Banner Faculty
David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

ProCE Banner Faculty
Egbert F. Smit, MD, PhD

Professor of Pulmonary Medicine
Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands

ProCE Banner Faculty
Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC).

Target Audience
This program is intended for medical oncologists and other healthcare professionals caring for patients with lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate current biomarker targets of ADCs for lung cancer treatment considering the rationale, abnormal expression or mutational status in lung cancers, and guidance on testing and pathological assessment

  • Differentiate important defining characteristics between ADC therapies and how these attributes may influence efficacy and safety outcomes

  • Select patients who may benefit from HER2-targeted ADC therapy considering patient-specific factors, such as overall health, comorbidities, prior treatments, and proper pathological assessment

  • Appraise emerging clinical data evaluating the use of ADCs for the treatment of NSCLC and SCLC

  • Develop protocols for regular patient monitoring during and after ADC treatment to detect and manage adverse events promptly

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EBAC® Accreditation 

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1.0 external CE credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity.

CME Passport
662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Daiichi Sankyo, Inc.